LFST · LifeStance Health Group, Inc.
$12.08
-0.04 (-0.33%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$4.52B
Shares
382.06M
Volume · Oct 7
26.42K
Avg daily vol (3M)
4.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.12
Open$12.20
Day$11.92–12.32
52W close$4.81–13.38
Avg vol 30d5.1M
Short int16.3M · 4.3% float · 3.1d
Short vol72%
Last earningsAug 6, 2026
DataJun 2021–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.58B
Trailing 12 months
Net income (TTM)
$50.60M
Trailing 12 months
Revenue growth YoY
+26.1%
Year over year
Operating margin
4.9%
Trailing 12 months
P / E (TTM)
89.4
Trailing earnings · reciprocal yield 1.1%
FCF yield
3.8%
TTM · current market cap
Return on invested capital
3.9%
Trailing 12 months
Net cash
−$47.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
+121.8%
Trailing year
Short interest
4.3%
Latest settlement · 3.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+37%
above
Price vs 50-day avg
+0%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
85%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+85%
trailing
YTD return
+72%
this year
Relative strength
+74%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow
Distributing
2 of 292 funds reported for Sep 30 · net -376 sh shares
Insider flow
Distributing
Net -$377.8M over 90 days · 100% sells
Short interest
Rising
4.26% of float · ▲ +19.4% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
292 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+14%
Y/Y
Free cash flow
$110.0M
Valuation
P/E 89.4
rich
Buyback
$100.0M
authorized
Balance sheet
$31.8M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Revenue
· full year 2026
Initiated
$1.69B – $1.73B
prior FY $1.42B
midpoint +19.7% Y/Y
Center Margin
· full year 2026
Non-GAAP
Initiated
$570M – $594M
Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$215M – $235M
Guided vs delivered
· last 8 settled
Total revenue
full year 2024
guided $1.2B – $1.24B
$1.25B
Beat +2.5%
Total revenue
third quarter of 2024
guided $290M – $310M
$312.72M
Beat +4.2%
Total revenue
second quarter of 2024
guided $297M – $315M
$312.33M
In line
Full year revenue
full year 2023
guided $1.03B – $1.04B
$1.06B
Beat +2.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+37%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
85%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow
Distributing
2 of 292 funds reported for Sep 30 · net -376 sh shares
Insider flow
Distributing
Net -$377.8M over 90 days · 100% sells
Short interest
Rising
4.26% of float · ▲ +19.4% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
292 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $12 · 85%
Range high $13
vs 200-day avg +37%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 117.15M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 15.2% | Q2 2026 | — |
| Center Margin non-GAAP | 288.97M | Six Months Ended June 30, 2026 | — |
| Center Margin (% of revenue) non-GAAP | 35.2% | Q2 2026 | — |
| Centers | 550 | as of June 30, 2026 | — |
| Clinician base | 8,542 | Q2 2026 | — |
| Free Cash Flow non-GAAP | $87.9M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by (used in) operating activities 99.9M
-12M Purchases of property and equipment
= Free Cash Flow 87.9M
|
|||
| Net clinician adds | 193 | Q2 2026 | — |
| New centers opened | 6 | Q2 2026 | — |
| patient visits | 0.4M | the three months ended June 30, 2026 filing | — |
| Revenue growth | 26% | the three months ended June 30, 2026 filing | — |
| Total clinicians | 8,542 | as of June 30, 2026 | — |
| Total Revenue Per Visit (TRPV) | $166.6 | Q2 2026 | — |
| Total Visits | 2.61M | Q2 2026 | — |
| Tuck-in acquisitions completed | 1 | Q2 2026 | — |
| Visit volumes | 2.6M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LFST
this stock
LifeStance Health Group, Inc.
|
$4.52B | +72.2% | +13.9% | 89.4 | 4.3% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -7.4% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.7% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.1% | +0.9% | 10.0 | 2.5% |
|
FMS
Fresenius Medical Care AG
|
$12.08B | -5.9% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LFST | +1.9% | -5.3% | +85.0% | +0.8% | +72.2% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | 0.0% | -7.0% | +73.7% | -1.4% | +57.9% |
Capital returns
Buyback program
· as of Aug 5, 2026
Authorized
$100.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.